<DOC>
	<DOCNO>NCT00490074</DOCNO>
	<brief_summary>The purpose trial evaluate effect upon immune system two regimen preventive HIV vaccination healthy adult volunteer . Volunteers vaccinate DNA-C NYVAC-C vaccine , immune change assess , well safety vaccine . Volunteers follow 72 week .</brief_summary>
	<brief_title>Study Compare Immunogenicity Safety Two HIV Preventive Vaccinations Healthy Volunteers</brief_title>
	<detailed_description>Methods : randomise phase I/II international trial parallel group design , open participant investigator blind laboratory personnel , healthy volunteer . Vaccines strategy : 70 volunteer receive 3 DNA-C vaccination 1 NYVAC-C vaccination ; 70 volunteer receive 2 DNA-C vaccination 2 NYVAC-C vaccination . DNA-C : 2x2ml intra muscular right leave vastus lateralis ; NYVAC-C : 1 ml intramuscular non-dominant deltoid . Main outcome : 1. presence CD8/CD4+ T cell response define accord internationally agree criterion evaluation IFNgamma ELISPOT assay : - response env plus least one gag , pol , nef peptide pool , - week 26 28 ; 2. safety parameter . Secondary outcome : - cellular response , - antibody response , - grade 1 2 adverse event , - event include consider unrelated . Sample size : 140 volunteer Enrollment period : 9 month Patient 's participation duration : 78 week Study duration : 27 month</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>age 18 55 year day screen available followup duration study ( 78 week screen ) able give write informed consent low risk HIV willing remain duration study low risk HIV infection define : history inject drug use previous ten year gonorrhoea syphilis last six month high risk partner ( e.g . inject drug use , HIV positive partner ) either currently within past six month unprotected anal intercourse last six month , outside relationship regular partner know HIV negative unprotected vaginal intercourse last six month outside relationship regular known/presumed HIV negative partner willing undergo HIV test willing undergo genital infection screen heterosexually active female , use effective method contraception partner ( combined oral contraceptive pill ; injectable contraceptive ; IUCD ; consistent record condom use ; physiological anatomical sterility self partner ) 14 day prior first vaccination 4 month last , willing undergo urine pregnancy test prior vaccination heterosexually active male , use effective method contraception partner first day vaccination 4 month last vaccination French volunteer : subject register French Health ministry computerise file authorise participate clinical trial subject cover Health Insurance subject include ANRS vaccine research network volunteer pregnant lactate clinically relevant abnormality history examination include history grandmal epilepsy ; severe eczema ; allergy egg gentamicin ; severe allergic disease ; liver disease inadequate hepatic function ; haematological , metabolic gastrointestinal disorder ; uncontrolled infection ; autoimmune disease , immunodeficiency use immunosuppressives precede 3 month receipt live attenuate vaccine within 60 day vaccine within 14 day enrolment receipt blood product immunoglobin within 4 month screen participation another trial medicinal product , complete less 30 day prior enrolment history severe local general reaction vaccination define local : extensive , indurated redness swell involve anterolateral thigh major circumference arm , resolve within 72 hour general : fever &gt; = 39.5oC within 48 hour ; anaphylaxis ; bronchospasm ; laryngeal oedema ; collapse ; convulsion encephalopathy within 72 hour HIV 1/2 positive indeterminate screen positive hepatitis B surface antigen , hepatitis C antibody serology indicate active syphilis require treatment positive DNA/ANA antibody titre consider clinically relevant immunology laboratory grade 1 routine laboratory parameter ( see section 4.1.4 &amp; appendix 4 definition ) Note clarification 18th april 2008 : hyperbilirubinemia consider exclusion criterion confirm conjugated bilirubinemia unlikely comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>AIDS Vaccines</keyword>
	<keyword>Vaccines , DNA</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>